

Michael J Overman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/180270/publications.pdf>

Version: 2024-02-01

182
papers

13,314
citations

36203

51
h-index

26548

107
g-index

184
all docs

184
docs citations

184
times ranked

16022
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	1.4	5
2	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	0.8	283
3	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
4	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. <i>British Journal of Surgery</i> , 2022, 109, 489-492.	0.1	17
5	Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF ^{V600E} metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-12.	0.8	49
6	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, e004001.		45
7	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
8	Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. <i>Cancers</i> , 2022, 14, 1137.	1.7	5
9	Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2022, 234, 474-483.	0.2	13
10	Molecular Landscape of Small Bowel Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1287.	1.7	7
11	Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. <i>BMJ Open</i> , 2022, 12, e057693.	0.8	3
12	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
13	Inducing Hypermutability to Promote Anti-PD-1 Therapy Response. <i>Cancer Discovery</i> , 2022, 12, 1612-1614.	7.7	1
14	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
15	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	1.0	17
16	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 208-211.	3.0	56
17	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. <i>Clinical Cancer Research</i> , 2021, 27, 120-130.	3.2	21
18	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	2.1	61

#	ARTICLE	IF	CITATIONS
19	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.	0.6	0
20	Cancer of Unknown Primary Presenting as Boneâ€Predominant or Lymph Nodeâ€Only Disease: A Clinicopathologic Portrait. <i>Oncologist</i> , 2021, 26, e650-e657.	1.9	3
21	Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2021, 233, 82-89e1.	0.2	19
22	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
23	Virtual Clinical Trials in Oncologyâ€Overview, Challenges, Policy Considerations, and Future Directions. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 421-425.	1.0	14
24	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
25	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	3.2	28
26	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31
27	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.	3.2	25
28	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	3.2	14
29	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.	7.7	37
30	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 5041-5050.	1.3	35
31	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	1.3	10
32	Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. <i>JAMA Network Open</i> , 2021, 4, e2119934.	2.8	11
33	Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 223-232.e1.	0.6	2
34	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
35	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1663-1670.	3.2	30
36	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0

#	ARTICLE	IF	CITATIONS
37	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , 2021, 5, 94.	2.3	4
38	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	1.0	2
39	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	15.2	236
40	Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1Dâ€”A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	0.8	106
41	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1385-1394.	3.2	31
42	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 996-1002.	2.1	34
43	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	2.2	105
44	Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. <i>Scientific Reports</i> , 2020, 10, 13255.	1.6	17
45	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.	2.9	18
46	Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e207911.	2.8	59
47	Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. <i>Oncologist</i> , 2020, 25, e1807-e1811.	1.9	7
48	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	1.4	59
49	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. <i>Clinical Colorectal Cancer</i> , 2020, 19, e189-e199.	1.0	1
50	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
51	Modified gemcitabine plus nab–paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	1.3	9
52	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	1.6	10
53	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 73-81.	1.0	36
54	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62

#	ARTICLE	IF	CITATIONS
55	Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open, 2020, 5, e000960.	2.0	20
56	Letting go of the physical exam: embracing telehealth solutions to oncology. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.5	0
57	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	2.9	32
58	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncology, 2019, 5, e191870.	3.4	348
59	Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TIME to Respond. Clinical Cancer Research, 2019, 25, 5185-5187.	3.2	10
60	Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer, 2019, 19, 965.	1.1	12
61	Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports, 2019, 21, 5.	1.1	50
62	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. Journal of the National Cancer Institute, 2019, 111, 1131-1141.	3.0	116
63	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	1.8	17
64	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell, 2019, 35, 559-572.e7.	7.7	353
65	Clinical and molecular characterization of early-onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	2.0	212
66	Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. Oncologist, 2019, 24, 483-490.	1.9	8
67	Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist, 2019, 24, e384-e386.	1.9	8
68	Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	1.5	46
69	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1453-1461.	1.9	75
70	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 340-345.	2.9	29
71	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	3.3	237
72	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical Cancer Research, 2019, 25, 641-651.	3.2	21

#	ARTICLE	IF	CITATIONS
73	Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 402.	3.4	11
74	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability-high (MSI-H) tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 670-670.	0.8	24
75	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1109-1133.	2.3	92
76	Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1135-1141.	2.3	45
77	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 1869-1874.	1.1	31
78	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
79	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	2.0	35
80	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.	3.0	26
81	Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. <i>Oncologist</i> , 2018, 23, 277-e26.	1.9	34
82	Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.	3.0	53
83	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018, 67, 1095-1102.	6.1	19
84	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <i>Annals of Surgical Oncology</i> , 2018, 25, 179-187.	0.7	26
85	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
86	Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e103-e108.	0.2	3
87	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
88	Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 239-247.	1.8	96
89	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. <i>BMC Medical Research Methodology</i> , 2018, 18, 169.	1.4	6
90	Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea. , 2018, 08, .		0

#	ARTICLE	IF	CITATIONS
91	Facile profiling of molecular heterogeneity by microfluidic digital melt. <i>Science Advances</i> , 2018, 4, eaat6459.	4.7	37
92	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. <i>JAMA Oncology</i> , 2018, 4, 1041.	3.4	4
93	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	6.9	30
94	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	1.3	24
95	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	1.0	34
96	Bioactive lipid metabolism in platelet "first responder" and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 439-454.	2.7	14
97	Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury. <i>Oncotarget</i> , 2018, 9, 34857-34858.	0.8	6
98	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017, 122, 146-151.	0.3	45
99	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
100	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	3.2	70
101	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	1.9	40
102	Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?. <i>Journal of Hepatology</i> , 2017, 67, 10-11.	1.8	4
103	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546.	3.4	154
104	Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 3954-3963.	0.7	9
105	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	3.2	41
106	Underreporting of Research Biopsies from Clinical Trials in Oncology. <i>Clinical Cancer Research</i> , 2017, 23, 6450-6457.	3.2	15
107	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. <i>Annals of Surgical Oncology</i> , 2017, 24, 3667-3672.	0.7	7
108	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	0.7	32

#	ARTICLE	IF	CITATIONS
109	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2017, 18, 1182-1191.	5.1	2,058
110	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. <i>Annals of Surgical Oncology</i> , 2017, 24, 2646-2654.	0.7	30
111	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
112	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30
113	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017, 17, 331.	1.1	11
114	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	2.0	45
115	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
116	Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. <i>Surgery</i> , 2017, 161, 332-340.	1.0	50
117	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UIMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017, 24, 187-193.	0.7	62
118	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25
119	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
120	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3531-3531.	0.8	26
121	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
122	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
123	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , 2016, 7, 67495-67506.	0.8	42
124	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	0.8	53
125	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
126	The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 213-221.	2.0	131

#	ARTICLE	IF	CITATIONS
127	Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 668.	1.1	11
128	Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2914-2919.	0.7	13
129	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
130	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
131	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
132	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 1352-1361.	2.9	81
133	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , 2016, 15, e1-e7.	1.0	41
134	Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. <i>Cancer Medicine</i> , 2016, 5, 239-247.	1.3	33
135	Ampullary Cancers Harbor <i>ELF3</i> Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. <i>Cell Reports</i> , 2016, 14, 907-919.	2.9	107
136	Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3501-3501.	0.8	90
137	Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. <i>PLoS ONE</i> , 2016, 11, e0154985.	1.1	22
138	<i>ABO</i> non-O type as a risk factor for thrombosis in patients with pancreatic cancer. <i>Cancer Medicine</i> , 2015, 4, 1651-1658.	1.3	18
139	A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 865-872.	2.3	12
140	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
141	Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. <i>Oncologist</i> , 2015, 20, e3-4.	1.9	3
142	A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2015, 22, 3640-3646.	0.7	26
143	A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. <i>Supportive Care in Cancer</i> , 2015, 23, 661-670.	1.0	14
144	Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. <i>Human Pathology</i> , 2015, 46, 1315-1322.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Goblet Cell Carcinoid Tumor, Mixed Goblet Cell Carcinoid-Adenocarcinoma, and Adenocarcinoma of the Appendix: Comparison of Clinicopathologic Features and Prognosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 782-790.	1.2	75
146	From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 3583-3590.	0.8	46
147	Epithelial-Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression. <i>Clinical Cancer Research</i> , 2015, 21, 899-906.	3.2	199
148	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2014, 22, 1223-1231.	1.0	86
149	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
150	Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. <i>Human Pathology</i> , 2014, 45, 1015-1023.	1.1	18
151	Small bowel adenocarcinomas—existing evidence and evolving paradigms. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 534-544.	12.5	140
152	Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 2792-2798.	1.1	23
153	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. <i>Investigational New Drugs</i> , 2013, 31, 1375-1383.	1.2	6
154	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series. <i>Acta Oncologica</i> , 2013, 52, 1044-1046.	0.8	2
155	High-level Microsatellite Instability in Appendiceal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1192-1200.	2.1	43
156	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. <i>Oncologist</i> , 2013, 18, 1270-1277.	1.9	41
157	Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. <i>Journal of Clinical Oncology</i> , 2013, 31, 17-22.	0.8	273
158	Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix. <i>Annals of Surgery</i> , 2013, 257, 1072-1078.	2.1	91
159	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. <i>PLoS ONE</i> , 2013, 8, e65144.	1.1	50
160	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. <i>Blood</i> , 2013, 122, 580-580.	0.6	27
161	Rare but Real: Management of Small Bowel Adenocarcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 189-193.	1.8	12
162	Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). <i>Blood</i> , 2013, 122, 3028-3028.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Adjuvant Chemotherapy for Resected Periampullary Adenocarcinoma. JAMA - Journal of the American Medical Association, 2012, 308, 1855.	3.8	3
164	A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Annals of Surgical Oncology, 2012, 19, 1439-1445.	0.7	124
165	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 450-450.	0.8	0
166	Fatal Diffuse Alveolar Damage Associated with Oxaliplatin Administration. Clinical Colorectal Cancer, 2011, 10, 198-202.	1.0	16
167	Lost in Translation: A Fisherman's Tale. Journal of Clinical Oncology, 2011, 29, 3832-3833.	0.8	2
168	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer, 2010, 116, 316-322.	2.0	109
169	Weekly docetaxel, cisplatin, and 5-Fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer, 2010, 116, 1446-1453.	2.0	43
170	Prognostic value of lymph node evaluation in small bowel adenocarcinoma. Cancer, 2010, 116, 5374-5382.	2.0	93
171	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. Journal of Clinical Oncology, 2010, 28, 2549-2555.	0.8	188
172	Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncologica, 2010, 49, 474-479.	0.8	79
173	Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. Journal of Clinical Oncology, 2009, 27, 2598-2603.	0.8	208
174	Portal Hypertension Associated With Oxaliplatin Administration: Clinical Manifestations of Hepatic Sinusoidal Injury. Clinical Colorectal Cancer, 2009, 8, 225-230.	1.0	94
175	Recent advances in the management of adenocarcinoma of the small intestine. Gastrointestinal Cancer Research: GCR, 2009, 3, 90-6.	0.8	25
176	Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Investigational New Drugs, 2008, 26, 445-454.	1.2	74
177	Chemotherapy with 5-Fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer, 2008, 113, 2038-2045.	2.0	109
178	Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases. Clinical Colorectal Cancer, 2008, 7, 338-342.	1.0	0
179	Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors. Cancer Investigation, 2008, 26, 794-799.	0.6	62
180	EGFR-Targeted Therapies in Colorectal Cancer. Diseases of the Colon and Rectum, 2007, 50, 1259-1270.	0.7	32

#	ARTICLE	IF	CITATIONS
181	The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood, 2007, 110, 1289-1289.	0.6	1
182	Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thrombosis and Haemostasis, 2004, 92, 886-7.	1.8	4